These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 8128425)

  • 21. Comparative inhibition of extrinsic and intrinsic thrombin generation by standard heparin, a low molecular weight heparin and the synthetic ATIII-binding pentasaccharide.
    Lormeau JC; Herault JP
    Thromb Haemost; 1993 Feb; 69(2):152-6, 176. PubMed ID: 8384381
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Collaborative study of Japanese Pharmacopoeia Heparin Sodium Reference Standard (Control 871)].
    Yomota C; Hasegawa R; Komuro T; Okada S; Kimura T
    Eisei Shikenjo Hokoku; 1989; (107):148-51. PubMed ID: 2636920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of N-deacetylation and N-desulfation of heparin on its anticoagulant activity and in vivo disposition.
    Bjornsson TD; Schneider DE; Hecht AR
    J Pharmacol Exp Ther; 1988 Jun; 245(3):804-8. PubMed ID: 3164387
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Heparin and antiheparin in young children. 1. Report: development of a method for determining heparin and antiheparin in the antithrombin-thrombin system].
    Domula M; Weissbach G
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(5):808-23. PubMed ID: 6188669
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anticoagulant property of a semi-synthesized sodium beta-1,4-glucan sulfate.
    Wang ZM; Li L; Li B; Guo SY
    Yao Xue Xue Bao; 2006 Apr; 41(4):323-7. PubMed ID: 16856476
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Studies on plasma hypercoagulability. 1. Heparin resistance in various diseases and its relation to coagulation factors, anticoagulant therapy, platelet and heparin co-factor].
    Satake K
    Naika Hokan; 1969 Apr; 16(4):127-38. PubMed ID: 5816626
    [No Abstract]   [Full Text] [Related]  

  • 27. [The Choay domain -- the structure responsible for the anticoagulant action of heparins].
    Hemker HC; al Dieri R; Wagenvoord R; Béguin S
    Bull Acad Natl Med; 2003; 187(1):59-66; discussion 66-7. PubMed ID: 14556454
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The monitoring of heparin administration by screening tests in experimental dogs.
    Mischke R; Jacobs C
    Res Vet Sci; 2001 Apr; 70(2):101-8. PubMed ID: 11356088
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effect of heparin cofactor II on the antithrombin III activities measured by thrombin methods or factor Xa methods--fundamental studies and clinical studies using the plasma of pregnant women].
    Akai Y; Shiga S; Tohyama K; Shimatsu A; Ichiyama S
    Rinsho Byori; 2000 Sep; 48(9):867-71. PubMed ID: 11051806
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antithrombin III-independent effect of depolymerized holothurian glycosaminoglycan (DHG) on acute thromboembolism in mice.
    Nagase H; Kitazato KT; Sasaki E; Hattori M; Kitazato K; Saito H
    Thromb Haemost; 1997 Feb; 77(2):399-402. PubMed ID: 9157603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. AANA Journal course: update for nurse anesthetists--low molecular weight heparin: pharmacology and regional anesthetic implications.
    Thames BC; Allen DO
    AANA J; 2000 Aug; 68(4):357-64. PubMed ID: 11125607
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of low molecular weight heparins and unfractionated heparin after successive subcutaneous administration. A randomized controlled study in healthy volunteers.
    Pindur G; Heiden M; Köhler M
    Arzneimittelforschung; 1993 May; 43(5):542-7. PubMed ID: 8392345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The APTT response of pregnant plasma to unfractionated heparin.
    Chunilal SD; Young E; Johnston MA; Robertson C; Naguit I; Stevens P; Galashan D; Oskamp ML; Brennan B; Ginsberg JS
    Thromb Haemost; 2002 Jan; 87(1):92-7. PubMed ID: 11848463
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How useful is the monitoring of (low molecular weight) heparin therapy by anti-Xa assay? A laboratory perspective.
    Favaloro EJ; Bonar R; Aboud M; Low J; Sioufi J; Wheeler M; Lloyd J; Street A; Marsden K;
    Lab Hematol; 2005; 11(3):157-62. PubMed ID: 16174600
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro anticoagulation monitoring of low-molecular-weight heparin.
    Wang JQ; Shi XB; Yang JG; Hu DY
    Chin Med J (Engl); 2009 May; 122(10):1199-202. PubMed ID: 19493471
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative performance of three anti-factor Xa heparin assays in patients in a medical intensive care unit receiving intravenous, unfractionated heparin.
    Lehman CM; Rettmann JA; Wilson LW; Markewitz BA
    Am J Clin Pathol; 2006 Sep; 126(3):416-21. PubMed ID: 16880140
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Age-related differences in heparin response.
    Ignjatovic V; Furmedge J; Newall F; Chan A; Berry L; Fong C; Cheng K; Monagle P
    Thromb Res; 2006; 118(6):741-5. PubMed ID: 16360197
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The significance of TFPI in clotting assays--comparison and combination with other anticoagulants.
    Nordfang O; Kristensen HI; Valentin S; Ostergaard P; Wadt J
    Thromb Haemost; 1993 Sep; 70(3):448-53. PubMed ID: 8259547
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Coagulation Inhibitor Potential: a study of assay variables.
    Andresen MS; Abildgaard U
    Thromb Res; 2005; 115(6):519-26. PubMed ID: 15792684
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Low-molecular weight heparins. Prospects in 1985].
    Aiach M; Fiessinger JN; Vitoux JF; Roncato M
    Ann Med Interne (Paris); 1986; 137(6):503-6. PubMed ID: 3545002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.